ATE230597T1 - Verwendung einer zusammensetzung aus h+, k+ - atpase-inhibitoren und glucocortikoiden zur behandlung von nasenpolypen - Google Patents
Verwendung einer zusammensetzung aus h+, k+ - atpase-inhibitoren und glucocortikoiden zur behandlung von nasenpolypenInfo
- Publication number
- ATE230597T1 ATE230597T1 AT97945135T AT97945135T ATE230597T1 AT E230597 T1 ATE230597 T1 AT E230597T1 AT 97945135 T AT97945135 T AT 97945135T AT 97945135 T AT97945135 T AT 97945135T AT E230597 T1 ATE230597 T1 AT E230597T1
- Authority
- AT
- Austria
- Prior art keywords
- glucocorticoids
- treatment
- composition
- nasal polyps
- atpase inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9603725A SE9603725D0 (sv) | 1996-10-11 | 1996-10-11 | New teatment |
PCT/SE1997/001651 WO1998016228A1 (en) | 1996-10-11 | 1997-10-01 | USE OF AN H+, K+-ATPase INHIBITOR IN THE TREATMENT OF NASAL POLYPS |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE230597T1 true ATE230597T1 (de) | 2003-01-15 |
Family
ID=20404214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT97945135T ATE230597T1 (de) | 1996-10-11 | 1997-10-01 | Verwendung einer zusammensetzung aus h+, k+ - atpase-inhibitoren und glucocortikoiden zur behandlung von nasenpolypen |
Country Status (34)
Country | Link |
---|---|
EP (1) | EP0946175B1 (de) |
JP (1) | JP4100713B2 (de) |
KR (1) | KR100510812B1 (de) |
CN (1) | CN1146416C (de) |
AR (1) | AR008886A1 (de) |
AT (1) | ATE230597T1 (de) |
AU (1) | AU738310B2 (de) |
BR (1) | BR9711896A (de) |
CA (1) | CA2268305C (de) |
CZ (1) | CZ298799B6 (de) |
DE (1) | DE69718347T2 (de) |
DK (1) | DK0946175T3 (de) |
EE (1) | EE04043B1 (de) |
ES (1) | ES2188995T3 (de) |
HK (1) | HK1022848A1 (de) |
HU (1) | HUP0000036A3 (de) |
ID (1) | ID23692A (de) |
IL (1) | IL129324A0 (de) |
IS (1) | IS1930B (de) |
MY (1) | MY117918A (de) |
NO (1) | NO321007B1 (de) |
NZ (1) | NZ334786A (de) |
PL (1) | PL190902B1 (de) |
PT (1) | PT946175E (de) |
RS (1) | RS49599B (de) |
RU (1) | RU2197966C2 (de) |
SA (1) | SA97180641B1 (de) |
SE (1) | SE9603725D0 (de) |
SK (1) | SK284252B6 (de) |
TR (1) | TR199900770T2 (de) |
TW (1) | TW568784B (de) |
UA (1) | UA59374C2 (de) |
WO (1) | WO1998016228A1 (de) |
ZA (1) | ZA978842B (de) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5840737A (en) | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
US6489346B1 (en) | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US6846799B1 (en) * | 1998-08-18 | 2005-01-25 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
US7354894B2 (en) | 1998-08-18 | 2008-04-08 | The Regents Of The University Of California | Preventing airway mucus production by administration of EGF-R antagonists |
RS50273B (sr) | 1998-08-18 | 2009-07-15 | The Regents Of The Univeristy Of California, | Antagonisti receptora epidermalnog faktora rasta za lečenje hipersekrecije mukusa u plućima |
JP4543553B2 (ja) * | 1999-03-03 | 2010-09-15 | オプティノーズ アズ | 鼻用の送り込み装置 |
EP1453493A2 (de) * | 2001-11-19 | 2004-09-08 | ALTANA Pharma AG | Reversibele protonpumpen-hemmer zur behandlung von atemwegserkrankungen |
US20050131026A1 (en) * | 2002-03-14 | 2005-06-16 | Atlanta Pharma Ag | Use of proton pump inhibitors for the treatment of airway disorders |
US20050165041A1 (en) * | 2002-05-07 | 2005-07-28 | Altana Pharma Ag | Combination for the treatment of airway disorders |
AU2003227710A1 (en) * | 2002-05-07 | 2003-11-11 | Altana Pharma Ag | New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders |
FR2845915B1 (fr) * | 2002-10-21 | 2006-06-23 | Negma Gild | Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien |
JP4755495B2 (ja) | 2002-12-12 | 2011-08-24 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 組合せ医薬品 |
US8993599B2 (en) | 2003-07-18 | 2015-03-31 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
WO2005025578A1 (en) | 2003-09-16 | 2005-03-24 | Altana Pharma Ag | Use of ciclesonide for the treatment of respiratory diseases |
US8906940B2 (en) | 2004-05-25 | 2014-12-09 | Santarus, Inc. | Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them |
CN104408249B (zh) * | 2014-11-24 | 2017-09-26 | 广州供电局有限公司 | 单芯电缆导体热性参数的确定方法及系统 |
KR101974504B1 (ko) * | 2017-04-10 | 2019-05-03 | 재단법인 아산사회복지재단 | 호산구성 비용종 동물모델 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1429184A (en) * | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
GB1571629A (en) * | 1977-11-30 | 1980-07-16 | Fisons Ltd | Pharmaceutical compositions containing beclomethasone dipropionate |
-
1996
- 1996-10-11 SE SE9603725A patent/SE9603725D0/xx unknown
-
1997
- 1997-01-10 UA UA99042004A patent/UA59374C2/uk unknown
- 1997-10-01 EE EEP199900118A patent/EE04043B1/xx not_active IP Right Cessation
- 1997-10-01 CZ CZ0122999A patent/CZ298799B6/cs not_active IP Right Cessation
- 1997-10-01 KR KR10-1999-7003115A patent/KR100510812B1/ko not_active IP Right Cessation
- 1997-10-01 BR BR9711896A patent/BR9711896A/pt not_active Application Discontinuation
- 1997-10-01 AU AU46409/97A patent/AU738310B2/en not_active Ceased
- 1997-10-01 CA CA002268305A patent/CA2268305C/en not_active Expired - Fee Related
- 1997-10-01 HU HU0000036A patent/HUP0000036A3/hu unknown
- 1997-10-01 ID IDW990139D patent/ID23692A/id unknown
- 1997-10-01 SK SK384-99A patent/SK284252B6/sk unknown
- 1997-10-01 PL PL332692A patent/PL190902B1/pl not_active IP Right Cessation
- 1997-10-01 JP JP51824698A patent/JP4100713B2/ja not_active Expired - Fee Related
- 1997-10-01 ES ES97945135T patent/ES2188995T3/es not_active Expired - Lifetime
- 1997-10-01 RS YUP-163/99A patent/RS49599B/sr unknown
- 1997-10-01 DK DK97945135T patent/DK0946175T3/da active
- 1997-10-01 RU RU99109596/14A patent/RU2197966C2/ru not_active IP Right Cessation
- 1997-10-01 NZ NZ334786A patent/NZ334786A/xx unknown
- 1997-10-01 EP EP97945135A patent/EP0946175B1/de not_active Expired - Lifetime
- 1997-10-01 TR TR1999/00770T patent/TR199900770T2/xx unknown
- 1997-10-01 DE DE69718347T patent/DE69718347T2/de not_active Expired - Fee Related
- 1997-10-01 CN CNB971985847A patent/CN1146416C/zh not_active Expired - Fee Related
- 1997-10-01 AT AT97945135T patent/ATE230597T1/de not_active IP Right Cessation
- 1997-10-01 IL IL12932497A patent/IL129324A0/xx not_active IP Right Cessation
- 1997-10-01 PT PT97945135T patent/PT946175E/pt unknown
- 1997-10-01 WO PCT/SE1997/001651 patent/WO1998016228A1/en active IP Right Grant
- 1997-10-02 ZA ZA9708842A patent/ZA978842B/xx unknown
- 1997-10-07 TW TW086114622A patent/TW568784B/zh not_active IP Right Cessation
- 1997-10-07 MY MYPI97004697A patent/MY117918A/en unknown
- 1997-10-08 AR ARP970104655A patent/AR008886A1/es unknown
- 1997-11-23 SA SA97180641A patent/SA97180641B1/ar unknown
-
1999
- 1999-04-06 NO NO19991619A patent/NO321007B1/no unknown
- 1999-04-08 IS IS5021A patent/IS1930B/is unknown
-
2000
- 2000-04-03 HK HK00102015A patent/HK1022848A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE230597T1 (de) | Verwendung einer zusammensetzung aus h+, k+ - atpase-inhibitoren und glucocortikoiden zur behandlung von nasenpolypen | |
DE69739758D1 (de) | Vakzine zur behandlung von lymphomen und leukämie | |
DE50009504D1 (de) | Verwendung von retigabin zur behandlung von neuropathischen schmerzen | |
DE60019556D1 (de) | 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit | |
DE60023128D1 (de) | Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen | |
DE69941566D1 (de) | N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie | |
DE60143061D1 (de) | Verwendung von Botulinum Toxin zur Behandlung von Gelenkschmerzen | |
DE69925306D1 (de) | Behandlung von kohlenwasserstoffgas | |
DE122009000012I1 (de) | Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen. | |
DE69720463D1 (de) | Sulfonamid-derivate und ihre verwendung zur behandlung von zns-erkrankungen | |
DE69835031D1 (de) | Neue anti-hiv immunogene (toxoide), herstellungsverfahren und verwendungen zur behandlung und vorbeugung von aids | |
DE60019158D1 (de) | Neue oxabispidin-verbindungen zur behandlung von herzarrhythmien | |
DE60019555D1 (de) | 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit | |
DE10082139T1 (de) | Zusammensetzung zur Behandlung von Reibungspaaren | |
DE69841984D1 (de) | Zusammensetzung aus nanokapseln zur behandlung von intraarticulaeren erkrankungen | |
ATE279386T1 (de) | Retinoide zur behandlung von emphysem | |
DE69833645D1 (de) | Neue therapeutische kombinationen aus mirtazapin und antipsychotika, zur behandlung oder prophylaxe von psychotischen störungen | |
DE60030861D1 (de) | Verwendung von escitalopram zur Behandlung von generalisierten Angstzuständen | |
DE69405919D1 (de) | Zusammensetzungen zur Behandlung von Keratinfasern | |
ATE418552T1 (de) | Substituierte amino-furan-2-yl-essigsaure- und amino-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz | |
DE50105735D1 (de) | Chlorzoxazon zur behandlung von psoriasis | |
ATE204705T1 (de) | Pflaster zur behandlung von pflanzen | |
DE60018200D1 (de) | Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen | |
DE69940971D1 (de) | Verwendung von erythropoietin zur behandlung von primärer hämochromatosen | |
DE60117122D1 (de) | Verwendung von mirtazapin zur behandlung von schlafstörungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0946175 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |